Bladder Cancer

"It is erdafitinib’s time to shine," says Arlene O. Siefker-Radtke, MD.

“At this point, we really have to consider the hard work and next steps of setting up multi-institutional databases and registries aimed at drilling down on patient and provider factors and medical decision-making around this diagnosis,” says James Ferguson III, MD, PhD.

The EV-302 trial is the confirmatory trial for the FDA’s accelerated approval of pembrolizumab plus enfortumab vedotin for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma.

“We found that over 40% of patients with muscle-invasive bladder cancer are not receiving cystectomy or trimodal therapy,” says James Ferguson III, MD, PhD.

“The ADVANCED-2 trial in NMIBC is an exciting opportunity to build on the favorable anti-tumor and safety data of TARA-002 presented earlier this year," says Gautam Jayram, MD.

Patients with MIBC were randomly assigned to receive APL-1202 in combination tislelizumab or to tislelizumab alone.

The first patient with NMIBC has been dosed with nadofaragene firadenovec-vncg as part of the Adstiladrin Early Experience Program.

BT8009 targets the tumor antigen Nectin-4, which has elevated expression levels in urothelial cancer.

The EU application for erdafitinib in urothelial carcinoma is supported by data from cohort 1 of the phase 3 THOR trial.

National MENtion It® campaign explores the impact stress has on men’s sexual and mental well-being.

Adding perioperative durvalumab to standard care for patients with resectable muscle-invasive urothelial carcinoma demonstrated promising event-free and overall survival rates in a phase 2 trial.

In the setting of refractory urothelial carcinoma, Jue Wang, MD, says it is essential to thoroughly understand a patient's molecular profile, comorbidities, and residual side effects from prior lines of therapy.

"We as a center prioritized using cisplatin and carboplatin for patients who are receiving curative intent chemotherapy," says Tian Zhang, MD.

The phase 3 THOR trial is the supporting trial for a supplemental New Drug Application for erdafitinib in urothelial carcinoma.

Erdafitinib previously received an accelerated approved for the treatment of adult patients with FGFR2/3-positive, previously-treated locally advanced or metastatic urothelial carcinoma.

“I think it's extremely exciting to be part of something that is possibly practice changing, potentially field changing,” says Sandip M. Prasad, MD, MPhil.

The Northwestern Medicine Department of Urology provides no-cost continuing medical education programs for urology professionals.

“I can tell you from a patient standpoint, I think we all agreed across the panel, there's going to be tremendous enthusiasm from patients about a nonsurgical option,” says Sandip M. Prasad, MD, MPhil.

“I think it's a very novel finding, and something completely new to urologic oncology, that a nonsurgical ablative option inside the body can actually make tumors go away,” says Sandip M. Prasad, MD, MPhil.

“For ATLAS, it was a different protocol. This was looking at giving the chemotherapy agent upfront,” says Sandip M. Prasad, MD, MPhil.

A total of 158 patients with NMIBC including tumors with stage carcinoma in situ, Ta, and T1 were enrolled in the prospective trial in mainland China.

"It's the first randomized trial that I'm aware of in urine markers looking at standard of care versus a marker-based approach," says Yair Lotan, MD.

Some patients with bladder cancer have been traveling to other regions for treatment if their location has no available cisplatin, explains Scott Tagawa MD.

The mitomycin-containing reverse thermal gel UGN-102 with or without TURBT reduced the risk of recurrence, progression, or death vs TURBT alone in patients with low-grade intermediate-risk non-muscle invasive bladder cancer.

"In the setting of BCG shortages, our patients need alternatives that do not deprive them of the chance of cure," says Ashish M. Kamat, MD, MBBS.

The phase 3 ATLAS and ENVISION trials are exploring UGN-102 for intravesical solution in patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.

Increased precision, decreased blood loss, and less risk of infection are among the benefits of robotic-assisted surgery, according to Hackensack Meridian Health.

The study is exploring the intravesically-delivered oncolytic immunotherapy cretostimogene grenadenorepvec in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

Pre-surgical treatment with the antibody-drug conjugate enfortumab vedotin elicited substantial antitumor activity in patients with cisplatin-ineligible muscle-invasive bladder cancer.

“Patients who present with [node-positive nonmetastatic bladder cancer] have a poor prognosis and should be counseled as to the most appropriate treatment, empowering them in their decision making with the knowledge that bladder preservation is a real alternative to radical surgery,” the authors wrote.